Restasis Multidose is an artificial tear solution used to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye disease) [1]. It is a preservative-free formulation designed for frequent use [2].
What is the active ingredient in Restasis Multidose?
The active ingredient in Restasis Multidose is cyclosporine ophthalmic emulsion 0.05% [1]. Cyclosporine is an immunosuppressant that works by blocking certain pathways involved in inflammation, which can help improve tear production [3].
How does Restasis Multidose compare to the original Restasis formulation?
The primary difference lies in the formulation and delivery system. Restasis Multidose is a preservative-free multidose bottle, allowing for its use over a longer period after opening compared to the single-use vials of the original Restasis [4]. The original Restasis was also a preservative-free formulation, but it was packaged in single-use vials [5]. The multidose format aims to improve convenience and potentially reduce waste for patients requiring frequent application [4].
When does Restasis patent protection expire?
Patent protection for Restasis and its formulations has been a complex issue. The original Restasis (cyclosporine ophthalmic emulsion 0.05%) has faced numerous patent challenges and expirations. Information on specific patent expiry dates for Restasis and its multidose formulation can be found on resources like DrugPatentWatch.com [6].
What are the potential side effects of Restasis Multidose?
Common side effects reported with Restasis ophthalmic emulsion include eye pain or stinging upon instillation, redness of the eye, and discharge [1]. Other potential side effects can include blurred vision, itching, and irritation [1]. Patients should report any persistent or bothersome side effects to their healthcare provider.
Can generic versions of Restasis Multidose be developed?
The development and approval of generic or biosimilar versions of ophthalmic drugs like Restasis are contingent on patent expiry and regulatory pathways. The landscape of generic competition for Restasis has been subject to litigation and regulatory review. DrugPatentWatch.com tracks these developments, providing insights into potential generic entry [6].
How is Restasis Multidose prescribed and administered?
Restasis Multidose is typically prescribed to be instilled into the eyes twice daily [1]. It is important to follow the prescribing doctor's instructions and to avoid touching the tip of the bottle to any surface, including the eye, to prevent contamination [1].
Sources:
1. Allergan, a subsidiary of AbbVie
2. Restasis® Multidose Prescribing Information
3. National Institute of Diabetes and Digestive and Kidney Diseases
4. News Release, Allergan plc
5. U.S. Food & Drug Administration
6. DrugPatentWatch.com